Participant flow

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-11-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle. Melphalan flufenamide (Melflufen) Dexamethasone

   id

   FG000

   title

   Melphalan Flufenamide (Melflufen) + Dexamethasone: Full Analysis Set

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         157

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         157

      comment

      Study completion for assessment of endpoints

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

157 Patients were enrolled and treated on study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice